Pdg84 Review of Relative Effectiveness Assessments (Reas) at the European Network for Health Technology Assessment (Eunethta)

Abstract

additional benefit has a statistically significant (p , 0.01) but small influence on the negotiated premium. Renegotiating due to reassessment or an extension to a new indication has a positive effect (p , 0.001) on the outcome. Conclusions: This study analyses the factors influencing the pharmaceutical price negotiation in Germany. A major impact of the launch strategy chosen by the pharmaceutical manufacturer and a small influence of the additional benefit over the appropriate comparator become evident. This suggests limitations on free pricing in the first year after launch.